PYC Therapeutics Limited (PYC.AX)
AUD 1.41
(-6.0%)
AUD 1.41
(-6.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -65.76 Million AUD | -331.05% |
| 2023 | -15.25 Million AUD | 45.84% |
| 2022 | -28.16 Million AUD | -59.09% |
| 2021 | -17.7 Million AUD | -174.74% |
| 2020 | -6.44 Million AUD | -287.77% |
| 2019 | -1.66 Million AUD | 47.2% |
| 2018 | -3.14 Million AUD | 68.34% |
| 2017 | -9.93 Million AUD | -40.52% |
| 2016 | -7.07 Million AUD | -379.28% |
| 2015 | -1.47 Million AUD | 63.3% |
| 2014 | -4.02 Million AUD | -122.57% |
| 2013 | -1.8 Million AUD | 34.98% |
| 2012 | -2.77 Million AUD | 46.55% |
| 2011 | -5.19 Million AUD | -11893.34% |
| 2010 | -43.35 Thousand AUD | 97.88% |
| 2009 | -2.04 Million AUD | 36.59% |
| 2008 | -3.22 Million AUD | 4.01% |
| 2007 | -3.35 Million AUD | -27.93% |
| 2006 | -2.62 Million AUD | 52.3% |
| 2005 | -5.5 Million AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -24.86 Million AUD | 0.0% |
| 2024 Q4 | -65.76 Million AUD | 0.0% |
| 2024 FY | -65.76 Million AUD | -331.05% |
| 2023 FY | -15.25 Million AUD | 45.84% |
| 2023 Q4 | -15.25 Million AUD | 0.0% |
| 2023 Q2 | -16.41 Million AUD | 0.0% |
| 2022 Q2 | -20.88 Million AUD | 0.0% |
| 2022 Q4 | -28.16 Million AUD | 0.0% |
| 2022 FY | -28.16 Million AUD | -59.09% |
| 2021 Q4 | -17.7 Million AUD | 0.0% |
| 2021 Q2 | -23.4 Million AUD | 0.0% |
| 2021 FY | -17.7 Million AUD | -174.74% |
| 2020 Q2 | -6.07 Million AUD | 0.0% |
| 2020 FY | -6.44 Million AUD | -287.77% |
| 2020 Q4 | -6.44 Million AUD | 0.0% |
| 2019 Q4 | -1.66 Million AUD | 0.0% |
| 2019 Q2 | -10.61 Million AUD | 0.0% |
| 2019 FY | -1.66 Million AUD | 47.2% |
| 2018 Q4 | -3.14 Million AUD | 0.0% |
| 2018 FY | -3.14 Million AUD | 68.34% |
| 2018 Q2 | -4.88 Million AUD | 0.0% |
| 2017 Q4 | -9.93 Million AUD | 0.0% |
| 2017 Q2 | -3.45 Million AUD | 0.0% |
| 2017 FY | -9.93 Million AUD | -40.52% |
| 2016 FY | -7.07 Million AUD | -379.28% |
| 2016 Q4 | -7.07 Million AUD | 0.0% |
| 2016 Q2 | -9.68 Million AUD | 0.0% |
| 2015 FY | -1.47 Million AUD | 63.3% |
| 2015 Q4 | -1.47 Million AUD | 0.0% |
| 2015 Q2 | -1.62 Million AUD | 0.0% |
| 2014 FY | -4.02 Million AUD | -122.57% |
| 2014 Q4 | -4.02 Million AUD | 0.0% |
| 2014 Q2 | -4.65 Million AUD | 0.0% |
| 2013 Q1 | -3.62 Million AUD | -30.57% |
| 2013 FY | -1.8 Million AUD | 34.98% |
| 2013 Q4 | -1.8 Million AUD | 0.0% |
| 2013 Q3 | -1.8 Million AUD | 50.2% |
| 2013 Q2 | -3.62 Million AUD | 0.0% |
| 2012 FY | -2.77 Million AUD | 46.55% |
| 2012 Q4 | -2.77 Million AUD | 0.0% |
| 2011 FY | -5.19 Million AUD | -11893.34% |
| 2011 Q4 | -5.19 Million AUD | 0.0% |
| 2010 Q4 | -43.35 Thousand AUD | 0.0% |
| 2010 FY | -43.35 Thousand AUD | 97.88% |
| 2009 FY | -2.04 Million AUD | 36.59% |
| 2009 Q4 | -2.04 Million AUD | 0.0% |
| 2008 Q4 | -3.22 Million AUD | 0.0% |
| 2008 FY | -3.22 Million AUD | 4.01% |
| 2007 Q4 | -3.35 Million AUD | 0.0% |
| 2007 FY | -3.35 Million AUD | -27.93% |
| 2006 FY | -2.62 Million AUD | 52.3% |
| 2006 Q4 | -2.62 Million AUD | 0.0% |
| 2005 FY | -5.5 Million AUD | 0.0% |
| 2005 Q4 | -5.5 Million AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | -18.89 Million AUD | -247.969% |
| Anatara Lifesciences Ltd | -982.1 Thousand AUD | -6595.99% |
| Zelira Therapeutics Limited | 5.06 Million AUD | 1397.76% |
| Biome Australia Limited | -1.56 Million AUD | -4107.928% |
| Patrys Limited | -2.24 Million AUD | -2834.928% |
| Orthocell Limited | -19.92 Million AUD | -230.051% |
| Imugene Limited | -91.56 Million AUD | 28.177% |
| Noxopharm Limited | -2.31 Million AUD | -2734.649% |
| Chimeric Therapeutics Limited | -3.05 Million AUD | -2054.005% |
| Prescient Therapeutics Limited | -10.16 Million AUD | -547.09% |
| Proteomics International Laboratories Limited | -6.32 Million AUD | -939.901% |
| Cynata Therapeutics Limited | -6.2 Million AUD | -959.748% |
| CSL Limited | 15.76 Billion AUD | 100.417% |
| Arovella Therapeutics Limited | -12.71 Million AUD | -417.223% |
| Bio-Gene Technology Limited | -709.55 Thousand AUD | -9167.993% |
| Clinuvel Pharmaceuticals Limited | -182.98 Million AUD | 64.062% |
| Starpharma Holdings Limited | -19.83 Million AUD | -231.594% |
| Nanollose Limited | -96.22 Thousand AUD | -68241.686% |
| Memphasys Limited | 4.13 Million AUD | 1690.227% |
| Invex Therapeutics Ltd | -6.02 Million AUD | -991.47% |
| NeuroScientific Biopharmaceuticals Limited | -4.95 Million AUD | -1227.41% |
| Amplia Therapeutics Limited | -1.82 Million AUD | -3506.17% |
| Botanix Pharmaceuticals Limited | -79.3 Million AUD | 17.081% |
| Island Pharmaceuticals Limited | -1.23 Million AUD | -5210.183% |
| Race Oncology Limited | -17.18 Million AUD | -282.584% |
| Nyrada Inc. | -4.76 Million AUD | -1278.835% |
| Telix Pharmaceuticals Limited | -105.79 Million AUD | 37.839% |
| Dimerix Limited | -21.99 Million AUD | -199.029% |
| PharmAust Limited | -9.71 Million AUD | -576.972% |
| Immutep Limited | -122.18 Million AUD | 46.18% |
| Clarity Pharmaceuticals Ltd | -136.5 Million AUD | 51.825% |
| Alterity Therapeutics Limited | -12.47 Million AUD | -426.944% |
| BTC Health Limited | -2.02 Million AUD | -3152.065% |
| Acrux Limited | -1.45 Million AUD | -4410.411% |
| Neuren Pharmaceuticals Limited | -17.09 Million AUD | -284.707% |
| Biotron Limited | -386.06 Thousand AUD | -16933.732% |
| Tissue Repair Ltd | -16.44 Million AUD | -299.985% |
| AdAlta Limited | -845.17 Thousand AUD | -7680.867% |
| Radiopharm Theranostics Limited | -18.57 Million AUD | -254.033% |
| Hexima Limited | -2.22 Million AUD | -2853.974% |
| AnteoTech Limited | -5 Million AUD | -1214.835% |
| Paradigm Biopharmaceuticals Limited | -17.58 Million AUD | -274.04% |
| Recce Pharmaceuticals Ltd | -3.39 Million AUD | -1836.372% |
| Avecho Biotechnology Limited | -5.32 Million AUD | -1133.979% |
| Actinogen Medical Limited | -9.13 Million AUD | -620.151% |
| Immuron Limited | -11.48 Million AUD | -472.647% |
| Argenica Therapeutics Limited | -15.91 Million AUD | -313.267% |